JP2023508469A5 - - Google Patents

Info

Publication number
JP2023508469A5
JP2023508469A5 JP2022539383A JP2022539383A JP2023508469A5 JP 2023508469 A5 JP2023508469 A5 JP 2023508469A5 JP 2022539383 A JP2022539383 A JP 2022539383A JP 2022539383 A JP2022539383 A JP 2022539383A JP 2023508469 A5 JP2023508469 A5 JP 2023508469A5
Authority
JP
Japan
Prior art keywords
compound
disorders
composition
anxiety
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539383A
Other languages
English (en)
Japanese (ja)
Other versions
JP7644122B2 (ja
JP2023508469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/067235 external-priority patent/WO2021134086A1/en
Publication of JP2023508469A publication Critical patent/JP2023508469A/ja
Publication of JP2023508469A5 publication Critical patent/JP2023508469A5/ja
Priority to JP2025029197A priority Critical patent/JP2025090628A/ja
Application granted granted Critical
Publication of JP7644122B2 publication Critical patent/JP7644122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539383A 2019-12-26 2020-12-28 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用 Active JP7644122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025029197A JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962953611P 2019-12-26 2019-12-26
US62/953,611 2019-12-26
US202063037044P 2020-06-10 2020-06-10
US63/037,044 2020-06-10
US202063093830P 2020-10-20 2020-10-20
US63/093,830 2020-10-20
PCT/US2020/067235 WO2021134086A1 (en) 2019-12-26 2020-12-28 Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025029197A Division JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2023508469A JP2023508469A (ja) 2023-03-02
JP2023508469A5 true JP2023508469A5 (cg-RX-API-DMAC7.html) 2023-12-20
JP7644122B2 JP7644122B2 (ja) 2025-03-11

Family

ID=74195194

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022539383A Active JP7644122B2 (ja) 2019-12-26 2020-12-28 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用
JP2025029197A Pending JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025029197A Pending JP2025090628A (ja) 2019-12-26 2025-02-26 アリールシクロヘキシルアミン誘導体及び精神障害の処置におけるそれらの使用

Country Status (10)

Country Link
US (2) US11344510B2 (cg-RX-API-DMAC7.html)
EP (1) EP4081301A1 (cg-RX-API-DMAC7.html)
JP (2) JP7644122B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131520A (cg-RX-API-DMAC7.html)
CN (2) CN119241381A (cg-RX-API-DMAC7.html)
AU (1) AU2020415511A1 (cg-RX-API-DMAC7.html)
CA (1) CA3165903A1 (cg-RX-API-DMAC7.html)
IL (1) IL294202A (cg-RX-API-DMAC7.html)
MX (1) MX2022007994A (cg-RX-API-DMAC7.html)
WO (1) WO2021134086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3043785T3 (da) 2013-09-13 2021-11-15 Univ Chiba Nat Univ Corp Anvendelse af r-ketamin og salt deraf som lægemidler
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
WO2021134086A1 (en) 2019-12-26 2021-07-01 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
LT4084791T (lt) 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
US20240197652A1 (en) 2021-05-25 2024-06-20 Awakn Ls Europe Holdings Limited Ketamine in the treatment of behavioral addictions
CA3225353A1 (en) * 2021-06-25 2022-12-29 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
AU2022374097A1 (en) * 2021-10-18 2024-03-14 Clearmind Labs Corp. 2-fluorodeschloroketamine for treatment of depression, including treatment-resistant depression
JP2025506178A (ja) * 2022-02-11 2025-03-07 ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド 精神状態及び障害を処置するための(ampar-pam)-nmda受容体拮抗薬組合せ療法
CN115677444A (zh) * 2022-10-26 2023-02-03 公安部第三研究所 同位素毒品代谢物标记化合物及其制备方法、用途
IL321707A (en) * 2022-12-28 2025-08-01 Gilgamesh Pharmaceuticals Inc Synthesis of 2-phenyl-2-amino-cyclohexan-1-one history
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
AU2024285405A1 (en) * 2023-06-05 2025-10-02 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of 2-phenyl-2-aminocyclohexan-1-one derivatives
US12157722B1 (en) 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB853775A (en) 1957-09-19 1960-11-09 Parke Davis & Co Pharmaceutical compositions and methods for producing phenylcyclohexane compounds
DE1668550A1 (de) * 1967-09-19 1971-07-22 Parke Davis & Co 2-Alkoxyalkylamino-2-phenylcyclohexanonverbindungen und ihre Saeure-Additionssalze und Verfahren zu ihrer Herstellung
US4065573A (en) 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
CA1105938A (en) 1976-06-03 1981-07-28 Daniel Lednicer 4-amino-4-arylcyclohexanone ketals
CA1100516A (en) 1976-06-03 1981-05-05 Daniel Lednicer 4-amino-4-arylcyclohexanones and their ketals
ES2297216T3 (es) 2002-06-21 2008-05-01 Suven Life Sciences Limited Indoles tetraciclicos arilsulfonil que tienen afinidad con el receptor de la serotonina.
BR0312175A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmacêutica, uso de um composto, método para o tratamento e método para reduzir a morbidez e a mortalidade associadas com o excesso de peso
SI1517909T1 (sl) 2002-06-21 2007-06-30 Suven Life Sciences Ltd Novi tetraciklični arilkarbonil indoli, ki imajo afiniteto za serotoninski receptor, uporabni kot terapevtska sredstva, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10252666A1 (de) 2002-11-11 2004-08-05 Grünenthal GmbH N-Piperidyl-cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1912970A2 (en) 2005-08-10 2008-04-23 Bayer Schering Pharma Aktiengesellschaft Acyltryptophanols for fertility control
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
EP1956016A1 (en) 2006-12-15 2008-08-13 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
HRP20140650T1 (hr) 2008-03-27 2014-09-26 Grünenthal GmbH Hidroksimetilcikloheksilamini
EP2385944A4 (en) 2009-01-09 2013-06-19 Harvard College FLUORINARY COMPOUNDS AND METHOD OF USE THEREOF
AU2010251930A1 (en) 2009-05-27 2011-11-24 Universite Libre De Bruxelles 3-alkyl-5-fluoroindole derivatives as myeloperoxidase inhibitors
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
CN104276993B (zh) 2013-07-12 2019-03-15 广东东阳光药业有限公司 吲哚衍生物及其在药物上的应用
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
JP7273731B2 (ja) 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
GB201808150D0 (en) 2018-05-18 2018-07-11 Small Pharma Ltd Therapeutic compounds
GB201716942D0 (en) 2017-10-16 2017-11-29 Small Pharma Ltd Therapeutic compounds
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
EP3505509A1 (en) 2017-12-29 2019-07-03 Université de Liège Methods for the preparation of arylcycloalkylamine derivatives
WO2019160057A1 (ja) 2018-02-15 2019-08-22 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
CN110343050B (zh) 2018-04-04 2021-09-24 上海键合医药科技有限公司 芳香类化合物及其制备方法和用途
KR102104953B1 (ko) * 2018-04-17 2020-04-27 삼육대학교 산학협력단 신규 케타민 유도체 및 이의 우울증의 예방 또는 치료 용도
TW202026281A (zh) 2018-12-12 2020-07-16 西班牙商艾斯提夫製藥股份有限公司 用於治療疼痛和疼痛相關病症之新吡咯啶–2– 甲酸衍生物
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2021134086A1 (en) * 2019-12-26 2021-07-01 Gilgamesh Pharmaceuticals, Inc. Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders
CN112174851A (zh) 2020-11-09 2021-01-05 广州万孚生物技术股份有限公司 一种氟胺酮半抗原、氟胺酮抗原及其制备方法和应用
CN113234036B (zh) 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Similar Documents

Publication Publication Date Title
KR100720290B1 (ko) 부프로피온 대사물, 이들의 합성방법 및 사용방법
JP2012521994A5 (cg-RX-API-DMAC7.html)
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP6321825B2 (ja) 神経形成を刺激することができるn−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用
JP7265990B2 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
JP2010138190A5 (cg-RX-API-DMAC7.html)
SI8310672A8 (en) Process for the production of cis-4-fenil-1,2,3,4-tetrahydro-1-naphthylamine derivates.
JP4198989B2 (ja) セロトニン作動性薬
JPH083035A (ja) 医薬の応答反応の増強
JP2005539068A5 (cg-RX-API-DMAC7.html)
JP2009527462A5 (cg-RX-API-DMAC7.html)
JP2022515293A5 (cg-RX-API-DMAC7.html)
JP2001511131A (ja) 月経前不快障害の処置
JP2024531437A5 (cg-RX-API-DMAC7.html)
JP2022539152A5 (cg-RX-API-DMAC7.html)
JP2019529460A5 (cg-RX-API-DMAC7.html)
JP2022541938A5 (cg-RX-API-DMAC7.html)
JP2013530953A5 (cg-RX-API-DMAC7.html)
JP2022048978A5 (ja) ケンペロール配糖体化合物を含む、老化により増殖が抑制された皮膚細胞の増殖を誘導するための組成物
JP2014518552A5 (cg-RX-API-DMAC7.html)
JP2008538582A (ja) 精神病性障害の治療または予防のための新規の治療的組み合わせ
JPH06500099A (ja) Cns疾病の処置におけるヘテロ環状アミノ―アルコール化合物の使用
JP2007530703A5 (cg-RX-API-DMAC7.html)
JP2007529492A5 (cg-RX-API-DMAC7.html)
JP4216072B2 (ja) ドーパミンd2受容体及びセロトニン再取り込み部位に対する高い親和性を有する8−{4−[3−(5−フルオロー1h−インドール−3−イル)−プロピル]−ピペラジン−1−イル}−2−メチル−4h−ベンゾ[1,4]オキサジン−3−オンメシラート